Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 28 Jun 2024 Planned End Date changed from 5 May 2027 to 31 Dec 2024.
- 10 Apr 2024 Planned End Date changed from 31 Dec 2024 to 5 May 2027.
- 19 Mar 2024 Planned End Date changed from 5 May 2027 to 31 Dec 2024.